Non-selective beta-blockers lower the risk of first decompensation in patients with cirrhosis and enduring clinically significant portal hypertension after etiological treatment
L. Turco,M.G. Taru,G. Vitale,F. Mirici Cappa,S. Berardi,A. Baldan,R. Di Donato,P. Pianta,V. Vero,L. Vizioli,M.C. Morelli,F. Piscaglia
DOI: https://doi.org/10.1016/j.dld.2024.01.004
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Background and aim Non-selective beta-blockers (NSBB) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous pressure gradient ³10 mmHg) with ongoing active etiological factor. Our aim was to examine the effect of NSBB on the risk of first decompensation in patients with cirrhosis and enduring CSPH after etiological treatment. Methods Single-center retrospective analysis of patients with compensated cirrhosis with enduring clinical evidence of CSPH (gastroesophageal varices -GEV- and/or spontaneous portosystemic collaterals- SPSS) after two years from etiological treatment. Primary endpoint was first decompensation (occurrence of variceal bleeding, ascites or hepatic encephalopathy) in patients on-NSBB vs off-NSBB. Results Final cohort included 406 patients. Baseline characteristics of patients on-NSBB (n=187) and off-NSBB (n=219) were comparable, except for signs of PH that were more pronounced in the on-NSBB group. During a mean follow-up of 32 months, 127 (31%) patients decompensated, with ascites being the most common (77%) decompensating event. Decompensation rates were significantly lower in patients on-NSBB (16% vs 44%, p<0,0001). The benefit of NSBB on decompensation was maintained in patients with small GEV (17% vs 43%, p<0,0001) (Figure A), in those with SPSS only (8% vs 43%, p=0,002) (Figure B) and in each different etiology, including HCV-cured cirrhosis (9% vs 32%, p<0,0001) (Figure C). At Cox regression analysis, Hemoglobin, Child-Pugh, MELD-Na, diabetes and bacterial infections were independent predictors of decompensation, while NSBB-use had a protective effect (HR 0,32, 95% CI 0,20-0,49; p<0,0001). Bacterial infections were the strongest trigger factor for decompensation (HR 2,43, 95% CI 1,65-3,58; p<0,0001). NSBB-use was independently associated with lower rate of bacterial infections (HR 0,36, 95% CI 0,22-0,58; p<0,0001), mitigating the risk of first decompensation (Figure D). Conclusion NSBB decrease the risk of first decompensation in patients with cirrhosis and enduring CSPH after etiological treatment.
gastroenterology & hepatology